|
|
Article: Biomira, Merck KGaA Miss Early Theratope Endpoints.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
Setting the bar high usually brings about one of two results: an exalting triumph or falling flat.
The result of Biomira Inc. and partner Merck KGaA ratcheting up the bar for Theratope in the interim analysis of their Phase III trial in metastatic breast cancer was not an exalting triumph, but that doesn't mean the product has completely fallen, either.
A Data Safety Monitoring Board (DSMB) conducted an interim analysis of the companies' 1,030-patient Phase III trial of Theratope vaccine and recommended the trial continue to its conclusion, expected in the second half of next year. Also, the DSMB said it had no safety ...